Formulary Watch Newsletter

To view this email as a web page, click here.

Drugs in Perspective: Opdivo (nivolumab)

Here’s a closer look at Opdivo (nivolumab).

Top 5 things to know about new lymphoma drug

Here are the top 5 things to know about obinutuzumab (Gazyva, Genentech) for the treatment of certain patients with follicular lymphoma.

Find out more

Top 5 things to know about new myeloma drug

Here are the top 5 things to know about ixazomib (Ninlaro, Takeda Pharmaceuticals) capsules for multiple myeloma.

FDA approves Varubi for chemotherapy-induced nausea

Chemotherapy-induced nausea and vomiting (CINV) is a debilitating, yet often preventable, side effect for patients undergoing chemotherapy for cancer. Here’s a look at rolapitant (Varubi, Tesaro) for the prevention of CINV.

First-of-its-kind myeloma drug approved

Daratumumab (Darzalex) was the first human anti-CD38 monoclonal antibody (mAb) approved anywhere in the world. CD38 is a surface protein that is expressed by most, if not all, multiple myeloma cells.

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.

CONNECT